Inside a $175M Deal: Tim McLoughlin & Joshua Hayes Live From RDU Startup Week
What's Shaping the Capital Raising Environment?
Raising a Down Round and How to Be Prepared
Developing an AI Policy for Your Startup
Due Diligence in AI: Thinking like your biggest critic
JONES DAY TALKS®: A Trip to the Dark Side – Venture Capital Down Rounds and Recaps
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
Embracing Change & Community: The Keys To Startup Success With Chris Heivly
The Best of Founder Shares: Highlights Wisdom of Season's Guests
A Conversation with Janade du Plessis of Launch Africa Ventures: Balancing Sustainable Development with ROI
The Force is Strong with this One – Success and Paying it Forward with Co-Founder of ChannelAdvisor and Spiffy Scot Wingo
Hunting Outsized Returns with Jason Caplain of Bull City Venture Partners
Through the Lens: From serial entrepreneur to neutral who gets deals done - Focus on Daniel Garrie
A View From the Starting Line – A Conversation with Teenpreneur Tierney Schmidt
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 159: Bob Quinn, Executive Director, and Adrianne Grimes, Director of Marketing and Comms, SCRA
From Accidental Entrepreneur to a $2.5M raise, with Cycle Labs' Josh Owen
The One Reason Startups Fail, with VentureSouth's Charlie Banks
When Two is Better Than One: Murphy’s Naturals and The Loading Dock Story with Philip Freeman
Huddling with Hutch adVENTURES: Behind the scenes with an early-stage venture capital firm
In a landmark legislative win for entrepreneurs, the “Big Beautiful Bill” was signed into law on July 4, 2025, overhauling how startups, founders, and early investors structure and grow their companies. Among the most...more
From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more
The life sciences industry depended historically on public offerings for fundraising to support costs of developing therapeutic pharmaceutical and biologic products. The average cost of discovering and developing these...more
An early-stage company can offer prospective investors an attractive investment opportunity, particularly if the company’s stock will qualify as “qualified small business stock” (QSBS) for US federal income tax purposes. This...more
On January 11, 2020, the Broad Institute, Verily Life Sciences, and Microsoft announced a strategic partnership to accelerate biomedical innovations through the Terra platform. Terra was originally developed by the Broad...more
The real estate needs of life sciences companies can be fluid and complex, with early stage companies typically needing smaller flexible space and later stage companies typically requiring larger build-to-suit space. With an...more
TAX CREDIT ON R&D - All companies also Innovative Start-ups that make investments in certain R&D activities can benefit from a particular tax credit (ex 3 Decree Law 145/2013)....more
Many large corporations have set up, or are in the process of setting up, in-house venture funds. At the same time, early and later-stage companies are looking for “smart money” investors – funds that bring strategic and...more